Britain and America have finalized a important commercial pact that will maintain zero duties on UK pharmaceutical exports going into the US market.
The Terms of the Deal
As part of the deal, the UK has committed to boost funding on drugs through the public health system. This move ensures that import taxes on these crucial goods will remain at zero for a period of three years.
This agreement follows recent threats to significantly raise import taxes on patented drug products, with increases discussed up to double the cost.
"This agreement with the United Kingdom strengthens the international landscape for innovative medicines and introduces much-needed fairness to U.S.–U.K. drug exports," an announcement noted.
Economic Significance
Medicines represent one of the Britain's most significant exports to the US, which is easily the biggest buyer for large British pharmaceutical firms.
Export figures show that in the year to the end of September, the UK shipped medicines valued at £11.1bn to the US. This value accounted for a significant portion of all goods exports in that timeframe.
"This guarantee secures jobs, stimulates capital expenditure and facilitates the UK to become a international leader for life sciences," a minister stated.
Specific NHS Changes
The deal includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be capped at 15%. Previously, rebates topped twenty percent.
Broader Context
The pact follows a long-running dispute between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were exacerbated by assertions that American patients were paying significantly more for the equivalent treatments than people in the other developed nations.
Recently, several large drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a share of its total funding over the past decade.
